IV iron dextran was the most cost-effective treatment, yielding 19.26 quality-adjusted life years at a cost of $157,500 vs 19.10 costing $152,900 for oral ferrous sulfate. HealthDay News — Intravenous ...
Intravenous (IV) iron use overall is associated with a “very low” risk for anaphylaxis, but iron dextran and ferumoxytol carry an increased risk relative to iron sucrose, according to new research.
A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in Blood ...
Experts highlight that IV iron not only helps combat anemic symptoms like fatigue and shortness of breath, but also significantly enhances women’s overall well-being. Unlike daily supplements, the ...
Two products commonly administered intravenously to replenish iron levels in the body have a much higher chance of provoking a severe allergic attack, according to Rutgers researchers who conducted a ...
During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue. Objectives: Medicare Part B payment ...
The comparative study aimed to analyze AEs as well as estimate the associated medical costs for 4 IV iron preparations. Hypersensitivity and anaphylactic reaction rates reported to the US Food and ...
IntravenoIron Drugs Market, By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others), and By ...
The chances of a severe allergic reaction being triggered by intravenous (IV) iron formulations for anemia are higher with some than others, but all pose a low risk, a new study says. Researchers ...
SOLUTIONS of degraded dextran have been shown to be a promising plasma substitute in a number of clinical trials. The practical problem in designing this substitute is to select dextran of the correct ...
IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate. (HealthDay News) — Intravenous (IV) iron dextran is the most cost-effective strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results